Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Boeing

Salesforce

Chevron

Disney

Dow Inc

Goldman Sachs

Intel

JPMorgan Chase & Co

Coca-Cola

McDonald's

Microsoft

NIKE

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are October's Dogs of the Dow: JNJ, AMGN, KO, GS, CVX, IBM, DOW, MMM, VZ, and WBA averaged a 4.99% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated October net-gains ranged 17.91%-45.47%, topped by WBA 10/2/23.

October Dogs Of The Dow: 3 Buyable, 7 Watchable

Bristol-Myers

Eli Lilly

Merck

Major drugmakers including Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Merck & Co Inc (NYSE:MRK) have agreed to participate in the Inflation Reduction Act's (IRA's) Medicare Drug Price Negotiation Program, the Biden administration said on Tuesday. The Inflation Reduction Act of 2022 granted the ability for Medicare to negotiate drug prices directly with manufacturers with the aim of reducing the costs of medications for seniors and other Medicare beneficiaries.

Drugmakers agree to participate in Medicare price negotiations

Sanofi

Sanofi revealed Tuesday that it had entered into an agreement with Janssen for the joint development and marketing of a vaccine candidate targeting extra-intestinal pathogenic E.coli.

Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment

A New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson in a trial over four plaintiffs' claims that they developed cancer from being exposed to the company's talc powder products.

Court tosses $223.8 million verdict against J&J in talc cancer case

Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson , to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.

Sanofi in agreement with Janssen to develop E. coli the vaccine candidate

PRESS RELEASE: REGULATED INFORMATION                                                                           3 October 2023, 7:00 CEST

Press Release Biocartis Group NV: Disclosure of transparency notification

LOS ANGELES--(BUSINESS WIRE)-- #JnJ--AIDS Healthcare Foundation (AHF) acknowledged today pharmaceutical company Johnson & Johnson's (J&J) announcement that it will not enforce its patent for the multi-drug resistant tuberculosis treatment SIRTURO (bedaquiline) for 134 low- and middle-income countries—a significant step in ending the global TB crisis for a preventable, treatable, and curable disease. “This is a win for public health and TB patients, but it took far too long to become a reality.

J&J Patent Move Must be First of Many, says AHF

AbbVie

Novartis

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

Pfizer

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

Drugmakers sign on to negotiate Medicare prices under protest

J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.

J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study

Procter & Gamble

In the new century, economic uncertainty often looms. Finding investment opportunities that can weather the storm is a quest every investor undertakes.

Recession-Proof Royals: 3 Stocks That Thrive in Tough Economic Times

There is no better way to create wealth than investing in stocks. Not gold, not bonds, not real estate.

Don't Miss Out: 3 Dividend Stocks to Buy on EVERY. SINGLE. DIP.

Apple

Exxon Mobil

Over the long run, dividend stocks have run circles around public companies that don't offer a payout. These seven income juggernauts are parsing out some of the largest nominal-dollar dividends in the world.

These 7 Dividend Stocks Pay $98 Billion Annually, Combined, to Their Shareholders

Global health aid agency Unitaid has written to Johnson & Johnson's (J&J) CEO Joaquin Duato, urging him to take "immediate action" to expand access to the company's tuberculosis drug bedaquiline.

Unitaid urges Johnson & Johnson to improve access to TB drug bedaquiline

Johnson & Johnson said on Thursday its cancer therapy combination met the main goal in a late-stage study testing it as a treatment for patients with a type of lung cancer.

J&J's lung cancer therapy combo succeeds in late-stage study

J&J recently spun off its slowest-growing business -- consumer health. The healthcare giant aims to focus its resources in its pharmaceuticals and medtech units, which together generated more than $79 billion in revenue last year.

3 Things About Johnson & Johnson That Smart Investors Know

The market had one of its worst weeks of the year, as the SPDR S&P 500 ETF Trust NYSE: SPY tumbled almost 3% lower. The selloff swept the market last week after the Federal Reserve signaled that interest rates will likely stay higher for longer than previously anticipated.

3 Blue Chip Safe Havens to Shield Your Portfolio

J&J's stock fell steeply following its share exchange offer for Kenvue stock, but dip buyers have since returned, auguring well for a further recovery. JNJ's best-in-class "A+" profitability grade provides robust support in a high-interest rate environment. Its renewed focus on its pharma and medtech business provides further valuation support. Management remains open to accretive M&A opportunities, bolstered by a robust balance sheet, which could lift its growth drivers further.

Johnson & Johnson: The Bull Case Can No Longer Be Ignored

Ally Financial

Bank of America

Citigroup

D.R. Horton

General Motors

Jefferies Financial Group Inc

Kraft Heinz

Louisiana-Pacific

Paramount Global

This Buffett holdings-list from Kiplinger first appeared 8/21/23 on line. Kiplinger, YCharts and Dogs of The Dow all track this Buffett/Berkshire batch. Here is your update from 9/20/23 YCharts data. 32 of 48 current Berkshire-Hathaway-owned-stocks pay dividends. As of 9/20/23 the top-ten ranged 2.87%-4.87% by annual-yield and 45 of 48 ranged -1.55% to 60.2% per broker-estimated target-price-upsides. Analyst-augured top-ten net-gains from Buffett's September dividend dogs ranged 21.35%-55.8% from UPS, KO, ALLY, BAC, KHC, LPX, DHI, C, PARA, and top pick GM per YCharts data.

The Buffett List: 5 Dividend Buys For September

Amazon

AutoZone

Chewy

Dollar General

General Mills

Kenvue

Here are some of the tickers on my radar for Wednesday, Sept. 20, taken directly from my reporter's notebook.

News for Johnson & Johnson Stock (JNJ)